Does the media refer more to RIGL or CDXS?

In the previous week, Codexis had 5 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Codexis and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.93 beat Codexis' score of 0.80 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Codexis 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACHV or CDXS more profitable?

Achieve Life Sciences has a net margin of 0.00% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -193.49% -111.88% Codexis -40.97% -68.09% -23.72%

Does the media prefer ACHV or CDXS?

In the previous week, Codexis had 7 more articles in the media than Achieve Life Sciences. MarketBeat recorded 9 mentions for Codexis and 2 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.94 beat Codexis' score of 0.80 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Codexis 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRWD or CDXS?

In the previous week, Codexis had 6 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for Codexis and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 1.59 beat Codexis' score of 0.80 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Codexis 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CDXS or MYGN?

In the previous week, Codexis had 3 more articles in the media than Myriad Genetics. MarketBeat recorded 9 mentions for Codexis and 6 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.82 beat Codexis' score of 0.80 indicating that Myriad Genetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, CDXS or VSTM?

Codexis has higher revenue and earnings than Verastem. Codexis is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $78.09M 1.75 -$43.97M -$0.37 N/A Verastem $30.91M 17.71 -$209.47M -$2.70 N/A

Is CDXS or VSTM more profitable?

Codexis has a net margin of -40.97% compared to Verastem's net margin of -391.17%. Codexis' return on equity of -68.09% beat Verastem's return on equity. Company Net Margins Return on Equity Return on Assets Codexis -40.97% -68.09% -23.72% Verastem -391.17% -486.40% -91.56%

Does the media refer more to CDXS or VSTM?

In the previous week, Codexis had 1 more articles in the media than Verastem. MarketBeat recorded 9 mentions for Codexis and 8 mentions for Verastem. Codexis' average media sentiment score of 0.80 beat Verastem's score of 0.60 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 2 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Verastem 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Codexis (CDXS) Competitors

$1.50 -0.05 (-3.23%)

As of 04:00 PM Eastern

Compare

CDXS vs. RIGL, ACHV, IRWD, MYGN, and VSTM

Should you buy Codexis stock or one of its competitors? MarketBeat compares Codexis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Codexis include Rigel Pharmaceuticals (RIGL), Achieve Life Sciences (ACHV), Ironwood Pharmaceuticals (IRWD), Myriad Genetics (MYGN), and Verastem (VSTM). These companies are all part of the "biotechnology" industry.

How does Codexis compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Rigel Pharmaceuticals presently has a consensus target price of $54.50, indicating a potential upside of 41.56%. Codexis has a consensus target price of $5.00, indicating a potential upside of 233.33%. Given Codexis' higher probable upside, analysts plainly believe Codexis is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Codexis had 5 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 9 mentions for Codexis and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.93 beat Codexis' score of 0.80 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 121.50% compared to Codexis' net margin of -40.97%. Rigel Pharmaceuticals' return on equity of 47.99% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Codexis	-40.97%	-68.09%	-23.72%

Rigel Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$299.77M	2.38	$367.02M	$18.72	2.06
Codexis	$78.09M	1.75	-$43.97M	-$0.37	N/A

Rigel Pharmaceuticals has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Codexis has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market.

Summary

Rigel Pharmaceuticals beats Codexis on 12 of the 16 factors compared between the two stocks.

How does Codexis compare to Achieve Life Sciences?

Achieve Life Sciences (NASDAQ:ACHV) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

Codexis has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.12	N/A
Codexis	$78.09M	1.75	-$43.97M	-$0.37	N/A

In the previous week, Codexis had 7 more articles in the media than Achieve Life Sciences. MarketBeat recorded 9 mentions for Codexis and 2 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.94 beat Codexis' score of 0.80 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Achieve Life Sciences has a net margin of 0.00% compared to Codexis' net margin of -40.97%. Codexis' return on equity of -68.09% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-193.49%	-111.88%
Codexis	-40.97%	-68.09%	-23.72%

33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 1.8% of Achieve Life Sciences shares are owned by insiders. Comparatively, 3.5% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Achieve Life Sciences presently has a consensus price target of $16.00, indicating a potential upside of 158.90%. Codexis has a consensus price target of $5.00, indicating a potential upside of 233.33%. Given Codexis' higher probable upside, analysts plainly believe Codexis is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Achieve Life Sciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Codexis has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market.

Summary

Codexis beats Achieve Life Sciences on 11 of the 16 factors compared between the two stocks.

How does Codexis compare to Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

In the previous week, Codexis had 6 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 9 mentions for Codexis and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 1.59 beat Codexis' score of 0.80 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Codexis	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.5% of Codexis shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ironwood Pharmaceuticals has higher revenue and earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.09	$24.02M	$0.60	6.33
Codexis	$78.09M	1.75	-$43.97M	-$0.37	N/A

Ironwood Pharmaceuticals has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market. Comparatively, Codexis has a beta of 2.5, meaning that its stock price is 150% more volatile than the broader market.

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, suggesting a potential upside of 64.04%. Codexis has a consensus target price of $5.00, suggesting a potential upside of 233.33%. Given Codexis' higher probable upside, analysts plainly believe Codexis is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.71
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Ironwood Pharmaceuticals has a net margin of 28.26% compared to Codexis' net margin of -40.97%. Ironwood Pharmaceuticals' return on equity of -39.65% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	28.26%	-39.65%	26.54%
Codexis	-40.97%	-68.09%	-23.72%

Summary

Ironwood Pharmaceuticals beats Codexis on 13 of the 17 factors compared between the two stocks.

How does Codexis compare to Myriad Genetics?

Codexis (NASDAQ:CDXS) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Codexis has a beta of 2.5, meaning that its share price is 150% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

78.5% of Codexis shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 3.5% of Codexis shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Codexis has higher earnings, but lower revenue than Myriad Genetics. Codexis is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$78.09M	1.75	-$43.97M	-$0.37	N/A
Myriad Genetics	$824.50M	0.61	-$365.90M	-$4.30	N/A

Codexis has a net margin of -40.97% compared to Myriad Genetics' net margin of -48.24%. Myriad Genetics' return on equity of -8.51% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Myriad Genetics	-48.24%	-8.51%	-4.48%

Codexis presently has a consensus target price of $5.00, indicating a potential upside of 233.33%. Myriad Genetics has a consensus target price of $6.50, indicating a potential upside of 22.18%. Given Codexis' higher possible upside, equities research analysts plainly believe Codexis is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Myriad Genetics	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Codexis had 3 more articles in the media than Myriad Genetics. MarketBeat recorded 9 mentions for Codexis and 6 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.82 beat Codexis' score of 0.80 indicating that Myriad Genetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Codexis beats Myriad Genetics on 8 of the 14 factors compared between the two stocks.

How does Codexis compare to Verastem?

Codexis (NASDAQ:CDXS) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Codexis has a beta of 2.5, suggesting that its share price is 150% more volatile than the broader market. Comparatively, Verastem has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

In the previous week, Codexis had 1 more articles in the media than Verastem. MarketBeat recorded 9 mentions for Codexis and 8 mentions for Verastem. Codexis' average media sentiment score of 0.80 beat Verastem's score of 0.60 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Verastem	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Codexis has higher revenue and earnings than Verastem. Codexis is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$78.09M	1.75	-$43.97M	-$0.37	N/A
Verastem	$30.91M	17.71	-$209.47M	-$2.70	N/A

Codexis currently has a consensus target price of $5.00, suggesting a potential upside of 233.33%. Verastem has a consensus target price of $14.40, suggesting a potential upside of 131.14%. Given Codexis' higher probable upside, analysts clearly believe Codexis is more favorable than Verastem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verastem	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Codexis has a net margin of -40.97% compared to Verastem's net margin of -391.17%. Codexis' return on equity of -68.09% beat Verastem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Verastem	-391.17%	-486.40%	-91.56%

78.5% of Codexis shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 1.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Codexis beats Verastem on 11 of the 17 factors compared between the two stocks.

Get Codexis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDXS vs. The Competition

Export

Metric	Codexis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$136.35M	$3.71B	$7.04B	$12.13B
Dividend Yield	N/A	2.18%	2.67%	9.43%
P/E Ratio	-4.05	22.08	27.30	23.78
Price / Sales	1.75	162.32	512.96	89.18
Price / Cash	N/A	59.51	26.39	46.66
Price / Book	2.68	7.93	10.27	6.10
Net Income	-$43.97M	$23.81M	$3.60B	$336.45M
7 Day Performance	-31.82%	-3.95%	-1.80%	-2.14%
1 Month Performance	-37.24%	-4.65%	-2.67%	-3.32%
1 Year Performance	-50.66%	32.78%	18.21%	13.49%

Codexis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDXS Codexis	2.3502 of 5 stars	$1.50 -3.2%	$5.00 +233.3%	-50.2%	$136.35M	$78.09M	N/A	250	Gap Down
RIGL Rigel Pharmaceuticals	4.249 of 5 stars	$36.82 -2.6%	$54.50 +48.0%	+85.4%	$699.38M	$294.28M	1.97	160	News Coverage Upcoming Earnings
ACHV Achieve Life Sciences	2.577 of 5 stars	$6.17 -2.2%	$16.00 +159.3%	+130.6%	$647.78M	N/A	N/A	20
IRWD Ironwood Pharmaceuticals	3.1964 of 5 stars	$3.79 -2.3%	$6.23 +64.5%	+379.0%	$632.67M	$296.15M	6.32	220	Positive News
MYGN Myriad Genetics	2.8711 of 5 stars	$5.70 +0.7%	$6.50 +14.0%	+22.5%	$534.58M	$824.50M	N/A	2,700	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDXS) was last updated on 7/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Codexis (CDXS) Competitors

CDXS vs. RIGL, ACHV, IRWD, MYGN, and VSTM

How does Codexis compare to Rigel Pharmaceuticals?

Summary

How does Codexis compare to Achieve Life Sciences?

Summary

How does Codexis compare to Ironwood Pharmaceuticals?

Summary

How does Codexis compare to Myriad Genetics?

Summary

How does Codexis compare to Verastem?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Codexis (CDXS) Competitors

CDXS vs. RIGL, ACHV, IRWD, MYGN, and VSTM

How does Codexis compare to Rigel Pharmaceuticals?

Do analysts prefer RIGL or CDXS?

Do institutionals & insiders believe in RIGL or CDXS?

Does the media refer more to RIGL or CDXS?

Is RIGL or CDXS more profitable?

Which has better earnings & valuation, RIGL or CDXS?

Which has more risk & volatility, RIGL or CDXS?

Summary

How does Codexis compare to Achieve Life Sciences?

Which has stronger valuation & earnings, ACHV or CDXS?

Does the media prefer ACHV or CDXS?

Is ACHV or CDXS more profitable?

Do institutionals & insiders believe in ACHV or CDXS?

Do analysts prefer ACHV or CDXS?

Which has more risk & volatility, ACHV or CDXS?

Summary

How does Codexis compare to Ironwood Pharmaceuticals?

Does the media prefer IRWD or CDXS?

Do institutionals and insiders have more ownership in IRWD or CDXS?

Which has stronger earnings & valuation, IRWD or CDXS?

Which has more risk & volatility, IRWD or CDXS?

Do analysts rate IRWD or CDXS?

Is IRWD or CDXS more profitable?

Summary

How does Codexis compare to Myriad Genetics?

Which has more risk and volatility, CDXS or MYGN?

Do insiders & institutionals have more ownership in CDXS or MYGN?

Which has higher valuation and earnings, CDXS or MYGN?

Is CDXS or MYGN more profitable?

Do analysts prefer CDXS or MYGN?

Does the media favor CDXS or MYGN?

Summary

How does Codexis compare to Verastem?

Which has more risk and volatility, CDXS or VSTM?

Does the media refer more to CDXS or VSTM?

Which has better earnings & valuation, CDXS or VSTM?

Do analysts rate CDXS or VSTM?

Is CDXS or VSTM more profitable?

Do institutionals & insiders have more ownership in CDXS or VSTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools